Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of MHB088C injection combined with MHB039A in advanced malignant solid tumors
CTR20253129Phase 2Active
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Aug 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MHB088C, MHB039A in Nonhematologic neoplasms, sponsored by Minghui Pharmaceutical, Inc.. Started Aug 2025; status: active.
02
Drugs
MHB088CMHB039A
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20253129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253129.